Mathias Hukkelhoven, PhD

Senior Vice President
Global Regulatory, Safety & Biometrics
Bristol-Myers Squibb

Mathias Hukkelhoven, PhD, joined Bristol-Myers Squibb (BMS) in March 2010 as the Senior Vice President, Global Regulatory, Safety & Biometrics and is also responsible for the R&D group in BMS China and the Clinical Pharmacology and Pharmacometrics group. He is responsible for setting regulatory strategy and driving execution of global regulatory, pharmacovigilance and biometrics plans for BMS. He is also responsible for leading the regulatory efforts across the product development and commercialization process to ensure optimal regulatory interactions at each step of the process — research and development, manufacturing, and commercialization. Prior to joining BMS, Math held the role of Chairman Portfolio Stewardship Board at Novartis Pharmaceuticals. From 2001 to 2009, he was the Senior Vice President, Global Head, Drug Regulatory Affairs at Novartis. He joined Sandoz/Novartis in 1993 as the interim Corporate Head of Drug Regulatory Affairs in Basel, Switzerland. Math transferred to the United States in 1994 and held progressively responsible positions including Vice President, Head of US Drug Regulatory Affairs. Prior to Novartis, Math was the International Drug Regulatory Affairs Group Leader at Hoffmann La Roche. He first joined the pharmaceutical industry with Organon in the Netherlands, following a role as Research Fellow of the Dutch Cancer Society with the University of Nijmegen, The Netherlands. Math has a wealth of experience in global regulatory affairs and drug development, evidenced by his contribution to more than 35 NCEs over his career to date. Math received his BS and PhD honors degrees in Biology and Biochemistry from the University of Nijmegen, the Netherlands.